Bayer hatte mit dem abgeschlossenen Verkauf der eigenen Tiermedizinsparte an Elanco Anfang August neben knapp 5,2 Milliarden Dollar in bar auch 72,9 Millionen Aktien von Elanco erhalten - … (August 3, 2020) – Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health. ACCC received further information from the parties. Required fields are marked *. “Avenge+ Fly is an established and popular brand, and will provide a strong constraint on Elanco in the hands of a future buyer. specialty products, which include immunomodulators, nutritionals, including vitamins, feed supplements and feed additives, and. Elanco Animal Health Incorporated proposes to acquire Bayer Aktiengesellschaft’s animal health business, which covers development and distribution of prescription and non-prescription products for farm and companion animals. Dadrch strich der Agrarchemie- und Pharmakonzern einen Milliardenbetrag ein. In Australia, this includes: Refer to the attached Public Competition Assessment. Bayer said it … Bayer hat ein großes Paket an Aktien des US-Tiermedizinspezialisten Elanco verkauft. Bayer’s sheep lice products include Avenge+ Fly, Piranha and Viper. AUSTRALIA’S competition regulator will not oppose Elanco’s acquisition of Bayer AG’s animal health business. An ACCC spokesman said the feedback from the market indicated that Avenge is a strong brand and would effectively address the ACCC’s competition concerns. Contributions that contravene our Comments Policy will not be published. Bayer hat zum Vollzug der Transaktion nach Abzug üblicher Kaufpreisanpassungen 5,17 Milliarden US-Dollar (vor Steuern) in bar sowie 72,9 Millionen Stammaktien von Elanco erhalten. We are strengthening our proven Innovation, Portfolio and Productivity (IPP) strategy, creating value for customers and the animals in their care. Both Bayer and Elanco sell a wide range of animal health products in Australia, including cattle tick prevention products and various parasiticides for companion and production animals. Bayer and Elanco do not have any manufacturing or R&D facilities based in Australia. ACCC is awaiting information from the parties. Bayer platzierte am Montag 54,5 Millionen Aktien der Elanco Animal Health Inc. zum Stückpreis von 30,25 US-Dollar. As noted in our media release, the ACCC will also issue a public competition assessment shortly – it will be on our public register when published: https://www.accc.gov.au/public-registers/mergers-registers/public-informal-merger-reviews/elanco-animal-health-incorporated-bayer-aktiengesellschaft%E2%80%99s-animal-health-business, Further information is available at Elanco Animal Health Incorporated – Bayer Aktiengesellschaft’s animal health business, Your email address will not be published. On 9 July 2020, the ACCC announced it had accepted an undertaking (the Undertaking) from Elanco Animal Health Incorporated and its subsidiary Elanco Australasia Pty Ltd pursuant to s 87B of the Competition and Consumer Act 2010 (Cth) in connection with Elanco Animal Health Incorporated’s proposal to acquire Bayer AG’s animal health business (the Proposed Acquisition). The ACCC will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands. Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health. Leverkusen, December 1, 2020 – Bayer today announced the placement of 54.5 million shares of Elanco Animal Health Incorporated (“Elanco”) at a price of 30.25 U.S. dollars per share pursuant to an SEC-registered public offering of Elanco shares on Monday. The ACCC said it will issue a public competition assessment shortly and publish it here. Bayer hatte mit dem abgeschlossenen Verkauf der eigenen Tiermedizinsparte an Elanco Anfang August neben knapp 5,2 Milliarden Dollar in bar auch 72,9 Millionen Aktien von Elanco erhalten - … Den Bruttoerlös bezifferte das Unternehmen in … Elanco wird damit zum zweitgrößten Anbieter in der Tiergesundheit weltweit. 0800 / 45 34 000 ### Produkte der ehemaligen Bayer Tiergesundheit, jetzt Teil von Elanco Creative Campus: Alfred-Nobel-Straße 10 40789 Monheim ### Customer Service … Die Aktienkomponente entspricht 15,5 Prozent der ausstehenden Aktien des US-Unternehmens. “Drontal in particular is a strong brand, and this divestment will remove any overlap between Bayer and Elanco in worming treatments.”. In Australia, this includes: pharmaceuticals, such as parasiticides and antimicrobials and analgesics, The acquisition of Bayer Animal Health is a key step in Elanco's journey to build a fit-for-purpose global animal health leader poised for the next era of growth. https://www.accc.gov.au/public-registers/mergers-registers/public-informal-merger-reviews/elanco-animal-health-incorporated-bayer-aktiengesellschaft%E2%80%99s-animal-health-business, Elanco Animal Health Incorporated – Bayer Aktiengesellschaft’s animal health business. Elanco Animal Health Incorporated proposes to acquire Bayer Aktiengesellschaft’s animal health business, which covers development and distribution of prescription and non-prescription products for farm and companion animals. GREENFIELD, Ind. Elanco’s dog and cat worming brands include Milbemax and Interceptor. Bayer and Elanco do not have any manufacturing or R&D facilities based in Australia. Bayer's sheep lice products include Avenge, Piranha and Viper. July 9 (Reuters) - ACCC: * AUSTRALIAN COMPETITION & CONSUMER COMMISSION SAYS ELANCO’S ACQUISITION OF BAYER’S ANIMAL HEALTH BUSINESS NOT OPPOSED Source text bit.ly/3iFcrit Further company coverage: ACCC announced it would not oppose the proposed acquisition, subject to a section 87B undertaking accepted by the ACCC. 01.12.2020 Your email address will not be published. “Without the divestment, Elanco would have significantly increased its market share in the supply of sheep lice treatments,” he said. Die Aktienkomponente entspricht 15,5 Prozent der ausstehenden Aktien des US-Unternehmens. The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs. Both Bayer and Elanco sell a wide range of animal health products in Australia, including various parasiticides for companion and production animals. Bayer’s sheep lice products include Avenge, Piranha and Viper. The transaction, valued at $6.89 billion, expands Elanco’s scale and capabilities, positioning the company for the long term as a leader in the attractive, durable animal health industry. Former provisional date for announcement of findings (30 April) is delayed. Bayer’s sheep lice products include Avenge+ Fly, Piranha and Viper. Bayer platzierte am Montag 54,5 Millionen Aktien der Elanco Animal Health Inc. zum Stückpreis von 30,25 US-Dollar. Bayer and Elanco do not have any manufacturing or R&D facilities based in Australia. COVID-19 (coronavirus) information for consumers, Unauthorised transfer of landline & internet services, Consumer rights for landline & internet services, COVID-19 (coronavirus) information for business, Industry associations & professional services, Competing fairly in professional services, Transmission services & facilities access, Retail electricity pricing inquiry 2017-2018, Monitoring & reporting for container stevedoring, Australian Competition & Consumer Commission, Compliance & enforcement policy & priorities, UniSA & ACCC Competition Law & Economics Workshop, Mergers & Competition Exemptions consultations, Digital platform services inquiry 2020-2025, Murray-Darling Basin water markets inquiry, Feminine hygiene products price monitoring, Foreign currency conversion services inquiry, Residential mortgage products price inquiry, Authorisations and notifications registers, Collective bargaining notifications register, Resale Price Maintenance notifications register. The future buyer or buyers of these brands will need to be approved by the ACCC. Closing date for submissions relating to the draft proposed divestment undertaking. Im vergangenen Jahr hat Bayer sein Tiermedizin-Geschäft für 7,56 Milliarden Dollar an das auf Tiermedizin spezialisierte Unternehmen Elanco verkauft. The ACCC will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands. Bayer hatte bereits angekündigt, das Paket wieder verkaufen zu wollen. The ACCC has preliminary competition concerns in relation to the transaction’s consolidation of sheep lice products, and of worming treatments commonly used for cats and dogs. Bayer ist ein Innovationsunternehmen mit einer über 150-jährigen Geschichte. Bayer and Elanco do not have any manufacturing or R&D facilities based in Australia. These products compete with Elanco’s Extinosad sheep lice product. ELANCO ANIMAL HEALTH AKTIE und aktueller Aktienkurs. The ACCC said it had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs. Für die 54,5 Millionen Elanco-Aktien fließen nun 1,65 Milliarden Dollar (1,38 Mrd Euro) in die Konzernkassen. “In relation to worming treatments for cats and dogs, the acquisition would have removed Bayer as Elanco’s closest competitor, leaving Elanco with many of the leading worming brands,” Mr Keogh said. FRANKFURT (Dow Jones)--Vier Monate nach dem Verkauf seiner Tiergesundheitssparte hat Bayer sich von einem Großteil der dabei übernommenen Elanco-Aktien getrennt. The ACCC is seeking views on a divestment undertaking offered by Elanco in relation to its proposed acquisition of Bayer Aktiengesellschaft's animal health business. Bayer beabsichtigt weiterhin, sich zu gegebener Zeit von seinem Anteil an Elanco zu trennen. pharmaceuticals, such as parasiticides and antimicrobials and analgesics. Bayer's sheep lice lines include Avenge, Piranha and Viper, which currently compete with Elanco's Extinosad. ACCC commenced informal review under the Informal Merger Review Process Guidelines. ACCC is awaiting further information from the parties. THE ACCC announced today it will not oppose Elanco’s acquisition of Bayer AG’s animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands. The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs. These products compete with Bayer’s Drontal, Profender and Droncit products. LEVERKUSEN (dpa-AFX) - Bayer (BAYZF.PK, BAYRY.PK, BYR.L) said that it has placed 54.5 million shares of Elanco Animal Health at a price of $30.25 per share. Bayer’s sheep lice products include Avenge, Piranha and Viper. A proposed divestment undertaking would see Elanco selling off the Drontal, Profender and Droncit worming brands, and Bayer's Avenge+Fly sheep lice brand to purchasers approved by the ACCC. Nachrichten zur Aktie Elanco Animal Health Inc Registered Shs | A2N6BH | ELAN | US28414H1032 The ACCC had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs. Elanco Animal Health Incorporated - Bayer Aktiengesellschaft’s animal health business, Bayer Aktiengesellschaft’s animal health business, Elanco Animal Health Incorporated and Elanco Australasia Pty Ltd - s87B undertaking - public version - 9 July 2020. Combines Elanco’s longstanding focus on the veterinarian with Bayer Animal Health’s direct-to-consumer expertise to open new opportunities to fuel growth. Bayer hat zum Vollzug der Transaktion nach Abzug üblicher Kaufpreisanpassungen 5,17 Milliarden US-Dollar (vor Steuern) in bar sowie 72,9 Millionen Stammaktien von Elanco erhalten. ACCC deputy chair Mick Keogh said Elanco’s acquisition was likely to raise competition concerns in the supply of sheep lice treatments. Scale and capabilities of the combined company position Elanco for the long term as a leader in the attractive, durable animal health industry. ACCC timeline recommenced. Former provisional date for announcement of findings (12 March) delayed. https://www.accc.gov.au. Unsere wissenschaftlichen Erfolge sollen helfen, das Leben der Menschen zu verbessern. Bayer hatte mit dem abgeschlossenen Verkauf der eigenen Tiermedizinsparte an Elanco Anfang August neben knapp 5,2 Milliarden Dollar in bar auch 72,9 Millionen Aktien von Elanco erhalten - das entsprach einem Anteil von rund 15,5 Prozent an den Amerikanern. Both Bayer and Elanco sell a wide range of animal health products in Australia, including various parasiticides for companion and production animals. Für 7,6 Milliarden Dollar erwirbt das US-Unternehmen Elanco die Animal Health GmbH von Bayer. Your comment will not appear until it has been moderated. Closing date for submissions from interested parties. ACCC requested further information from the parties. The commission sought feedback from interested parties before making its latest decision. Your comment will not appear until it has been moderated. … ACCC commenced market consultation on proposed s87B undertaking. # Kontakt ### Elanco Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg ### Kundenbetreuung: Tel. July 9 (Reuters) - ACCC: * AUSTRALIAN COMPETITION & CONSUMER COMMISSION SAYS ELANCO’S ACQUISITION OF BAYER’S ANIMAL HEALTH BUSINESS NOT OPPOSED Source text bit.ly/3iFcrit Further company coverage: Elanco has said it will sell Bayer’s Avenge+Fly if it can buy Bayer AG. The ACCC will not oppose Elanco's acquisition of Bayer AG's animal health business, after Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands.. Elanco will divest the sheep lice treatment Avenge+ Fly, as well as the cat and dog intestinal worm treatments Drontal, Profender and Droncit. That was the course it took earlier this year when US animal pharmaceutical company Elanco acquired the Bayer animal health business. Former provisional date for announcement of findings (18 June) is delayed. 0800 / 453 48 47 Fax 0800 / 723 40 83 E-Mail: kundenbetreuung@elanco.com ### Tierärztliche Fachberatung: Tel. Both Bayer and Elanco sell a wide range of animal health products in Australia, including cattle tick prevention products and various parasiticides for companion and production animals. At completion, Bayer will receive gross proceeds of approximately 1.649 billion U.S. dollars. On 9 July 2020, the ACCC announced its decision not to oppose the proposed acquisition by Elanco Animal Health Incorporated (Elanco) of Bayer Aktiengesellschaft’s (Bayer) Australian animal health business (the proposed acquisition) after accepting a section 87B undertaking to divest the Avenge+ Fly, Drontal, Profender and Droncit brands (the Undertaking). Click here if you wish Bayer PLC to keep you informed of products and marketing updates by email. The Australian Competition and Consumer Commission today said Elanco had provided a court-enforceable undertaking to divest four animal parasite treatment brands. Save my name, email, and website in this browser for the next time I comment.